These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1067 related articles for article (PubMed ID: 19803758)

  • 1. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.
    Grijalva CG; Griffin MR
    Expert Rev Vaccines; 2008 Feb; 7(1):83-95. PubMed ID: 18251696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-valent pneumococcal conjugate vaccine: new preparation. Prevents rare invasive infections in infants.
    Prescrire Int; 2002 Feb; 11(57):7-10. PubMed ID: 11985376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medical indications and effectiveness of the pneumococcal conjugate vaccine].
    Reinert RR
    Laryngorhinootologie; 2006 Apr; 85(4):291-8; quiz 299-300. PubMed ID: 16615030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 13-valent pneumococcal conjugate vaccine.
    Prescrire Int; 2011 Jan; 20(112):5-7, 9. PubMed ID: 21462782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
    Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe.
    Reinert RR; Paradiso P; Fritzell B
    Expert Rev Vaccines; 2010 Mar; 9(3):229-36. PubMed ID: 20218848
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
    Paradiso PR
    Clin Infect Dis; 2011 May; 52(10):1241-7. PubMed ID: 21507921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serious invasive pneumococcal disease in young children: the importance of vaccination].
    Haveman LM; Geelen SP; Sanders EA; Wolfs TF
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1917-20. PubMed ID: 12404904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine policy decisions: tension between science, cost-effectiveness and consensus?
    Zimmerman RK; Jackson RE
    Am Fam Physician; 2001 May; 63(10):1919, 1923. PubMed ID: 11388708
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(21):394-5. PubMed ID: 22647745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?
    Hanquet G; Perrocheau A; Kissling E; Bruhl DL; Tarragó D; Stuart J; Stefanoff P; Heuberger S; Kriz P; Vergison A; de Greeff SC; Amato-Gauci A; Celentano LP;
    Vaccine; 2010 May; 28(23):3920-8. PubMed ID: 20394721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2002 Jan; 28(ACS-2):1-32. PubMed ID: 12728645
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children.
    Shields B
    J Pediatr Health Care; 2001; 15(4):203-8; quiz 209-10. PubMed ID: 11462129
    [No Abstract]   [Full Text] [Related]  

  • 19. Pneumococcal conjugate vaccines. A review.
    Galiza EP; Heath PT
    Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with pneumococcal conjugate vaccine in Norway.
    Aaberge IS
    Expert Rev Vaccines; 2009 Feb; 8(2):159-65. PubMed ID: 19196196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.